Backlash builds against Novo’s Catalent takeover

When Novo Nordisk’s holding company announced plans to acquire contract manufacturer Catalent for $16.5 billion in February, the deal faced swift public backlash and an inquiry from the Federal Trade Commission. As the year winds down, the deal’s potential impact is still up in the air, and Big Pharma rivals have joined the chorus of opposition.